U.S. Markets closed

Allergan valuation attractive at current levels, says RBC Capital

RBC Capital believes that Allergan will be able to get itself out of the penalty box by using strategic levers to boost shareholder value. The firm lowered its price target on the stock to $105 from $119 but keeps an Outperform rating on the shares.